作者: Vonda K. Douglas , Leo I. Gordon , Charles L. Goolsby , Christine A. White , LoAnn C. Peterson
关键词:
摘要: Rituximab is a novel anti-CD20 monoclonal antibody used in the treatment of relapsed low-grade non-Hodgkin lymphoma. To determine impact this therapy on interpretation posttherapy specimens, we reviewed pretherapy and bone marrow peripheral blood morphologic flow cytometric findings for 20 patients who received rituximab. Nine had total 13 specimens; all were positive lymphoma before therapy. After therapy, 11 specimens interpreted as or suggestive based routine HE lymphoid infiltrates composed entirely T cells without B cells. We report that from treated with rituximab may mimic residual if examined by features alone. Familiarity finding use ancillary immunophenotypic studies will aid accurate specimens.